Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 17253814 | USE OF CYCLIC ADENOSINE MONOPHOSPHATE, DERIVATIVE OR PRODRUG THEREOF IN PREPARATION OF DRUG FOR PREVENTING AND/OR TREATING DEPRESSION | December 2020 | August 2023 | Abandon | 32 | 1 | 0 | No | No |
| 17252962 | METHODS AND AGENTS FOR MODULATING INFLAMMATION | December 2020 | June 2023 | Allow | 30 | 2 | 0 | Yes | No |
| 17116755 | COMPOSITIONS AND METHODS FOR TREATING RETINAL DEGRADATION | December 2020 | December 2022 | Allow | 24 | 2 | 0 | No | No |
| 17104808 | TLR7 AGONISTS | November 2020 | February 2023 | Allow | 27 | 1 | 0 | No | No |
| 17094541 | HIGHLY ACTIVE COMPOUNDS AGAINST COVID-19 | November 2020 | October 2022 | Allow | 23 | 1 | 0 | No | No |
| 17054409 | Composition and Methods for Treating Articulating Joint Disorders with Nucleoside Reverse Transcriptase Inhibitors | November 2020 | February 2023 | Allow | 27 | 4 | 0 | Yes | No |
| 17077267 | NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS | October 2020 | December 2022 | Allow | 25 | 2 | 0 | No | No |
| 17069429 | Stabilized Glycosaminoglycan Preparations and Related Methods | October 2020 | December 2022 | Abandon | 26 | 1 | 0 | No | No |
| 17065149 | TREATMENT OF HCV INFECTED PATIENTS WITH CIRRHOSIS | October 2020 | October 2022 | Allow | 25 | 1 | 0 | No | No |
| 17045929 | PACKAGING OLIGONUCLEOTIDES INTO VIRUS-LIKE PARTICLES | October 2020 | March 2024 | Allow | 41 | 0 | 1 | No | No |
| 17028314 | CANCER TREATMENTS BASED ON GEMCITABINE PRODRUGS | September 2020 | November 2022 | Abandon | 25 | 1 | 0 | No | No |
| 17025508 | METHODS OF SYNTHESIZING SUBSTITUTED PURINE COMPOUNDS | September 2020 | September 2022 | Allow | 24 | 1 | 0 | No | No |
| 16979836 | SUPERABSORBENT POLYMER AND METHODS OF MAKING AND USING THE SAME | September 2020 | January 2024 | Allow | 40 | 1 | 0 | No | No |
| 17017443 | HIGHLY ACTIVE COMPOUNDS AGAINST COVID-19 | September 2020 | November 2020 | Allow | 2 | 0 | 0 | No | No |
| 17009590 | MODULATORS OF 5'-NUCLEOTIDASE, ECTO AND THE USE THEREOF | September 2020 | February 2021 | Allow | 6 | 1 | 0 | No | No |
| 17005045 | CYCLIC DINUCLEOTIDE COMPOUNDS AS STING AGONISTS | August 2020 | February 2023 | Allow | 30 | 1 | 0 | No | No |
| 17001512 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | August 2020 | August 2022 | Allow | 24 | 1 | 0 | No | No |
| 16991765 | DIASTEREOSELECTIVE SYNTHESIS OF PHOSPHATE DERIVATIVES | August 2020 | November 2022 | Allow | 27 | 1 | 0 | No | No |
| 16930123 | 5-FLUOROURACIL COMPOUNDS | July 2020 | April 2022 | Allow | 21 | 2 | 0 | Yes | No |
| 16923396 | NEPRILYSIN INHIBITORS | July 2020 | August 2022 | Allow | 25 | 1 | 0 | No | No |
| 16921359 | N4-Hydroxycytidine and Derivatives and Anti-Viral Uses Related Thereto | July 2020 | September 2022 | Allow | 27 | 2 | 0 | Yes | No |
| 16909394 | METHOD OF INHIBITING OR REDUCING A VIRAL INFECTION | June 2020 | November 2022 | Allow | 28 | 1 | 0 | No | No |
| 16908416 | EFFICIENT AND SCALABLE SYNTHESES OF NICOTINOYL RIBOSIDES AND REDUCED NICOTINOYL RIBOSIDES, MODIFIED DERIVATIVES THEREOF, PHOSPHORYLATED ANALOGS THEREOF, ADENYLYL DINUCLEOTIDE CONJUGATES THEREOF, AND NOVEL CRYSTALLINE FORMS THEREOF | June 2020 | May 2023 | Allow | 34 | 1 | 1 | No | No |
| 16904888 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | June 2020 | May 2022 | Allow | 23 | 1 | 0 | No | No |
| 16899226 | GLUCOSE CONJUGATES OF TRIPTOLIDE, ANALOGS AND USES THEREOF | June 2020 | September 2022 | Abandon | 27 | 1 | 0 | No | No |
| 16894461 | CO-CRYSTAL FORMS OF A NOVOBIOCIN ANALOG AND PROLINE | June 2020 | May 2022 | Allow | 23 | 1 | 0 | No | No |
| 16886985 | Methods of Preparing Nicotinamide Riboside and Derivatives Thereof | May 2020 | December 2022 | Allow | 30 | 2 | 0 | Yes | No |
| 16878911 | GLYCOSYL HESPERETIN AND PROCESS FOR PRODUCING THE SAME AND USES THEREOF | May 2020 | May 2022 | Allow | 24 | 1 | 0 | No | No |
| 16876659 | PROCESSES FOR THE PREPARATION OF SGLT-2 INHIBITORS, INTERMEDIATES THEREOF | May 2020 | August 2022 | Allow | 27 | 1 | 0 | No | No |
| 16868010 | COMPOSITIONS AND METHODS DIRECTED TO TREATING LIVER FIBROSIS | May 2020 | March 2023 | Abandon | 35 | 0 | 1 | No | No |
| 16860768 | Composition and Methods of Treating Acne and Photoaging | April 2020 | January 2023 | Allow | 33 | 2 | 0 | No | No |
| 16854475 | METHODS AND SYSTEMS FOR NUCLEIC ACID PREPARATION AND CHROMATIN ANALYSIS | April 2020 | March 2023 | Allow | 35 | 2 | 0 | No | No |
| 16854196 | COMPOSITIONS AND METHODS FOR TREATMENT OF INFLAMMATORY DISORDERS | April 2020 | May 2022 | Allow | 25 | 1 | 0 | No | No |
| 16851217 | NOVEL COMPOUND OF 4'-THIONUCLEOSIDE, AS WELL AS PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF AND APPLICATION THEREOF | April 2020 | August 2022 | Abandon | 28 | 1 | 0 | No | No |
| 16850771 | SYNTHESIS OF ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | April 2020 | May 2022 | Allow | 25 | 1 | 0 | No | No |
| 16849934 | INORGANIC SALTS OF NICOTINIC ACID MONONUCLEOTIDE AS ANTI-AGING AGENTS | April 2020 | April 2023 | Abandon | 36 | 2 | 0 | No | No |
| 16849091 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | April 2020 | March 2022 | Allow | 23 | 0 | 0 | Yes | No |
| 16838660 | NUTRITIONAL FORMULATIONS USING HUMAN MILK OLIGOSACCHARIDES FOR MODULATING INFLAMMATION | April 2020 | January 2024 | Abandon | 45 | 4 | 0 | No | No |
| 16830745 | PROCESS FOR ISOLATING NUCLEIC ACIDS FROM SAMPLE MATERIALS | March 2020 | December 2023 | Allow | 45 | 3 | 0 | No | No |
| 16825024 | NOVEL 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | March 2020 | December 2021 | Allow | 21 | 1 | 0 | Yes | No |
| 16823704 | COMPOSITIONS AND METHODS FOR USING ACTIVATED CARBON PARTICLES FOR PURIFICATION OF NUCLEIC ACIDS | March 2020 | April 2023 | Abandon | 37 | 1 | 0 | No | No |
| 16648558 | Compositions and Methods for Treating Transthyretin (TTR) Mediated Amyloidosis | March 2020 | June 2023 | Allow | 39 | 2 | 0 | Yes | No |
| 16823144 | USE OF INOSINE FOR CANCER IMMUNOTHERAPY | March 2020 | July 2020 | Allow | 3 | 2 | 0 | Yes | No |
| 16629119 | DEGRADATION AGENT USING AUTOPHAGIC MECHANISM OF DAMAGED MITOCHONDRIA | March 2020 | August 2022 | Allow | 31 | 2 | 1 | Yes | No |
| 16805618 | Oligonucleotide Conjugation Process | February 2020 | September 2022 | Allow | 30 | 1 | 0 | No | No |
| 16799669 | CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE | February 2020 | August 2022 | Abandon | 30 | 1 | 0 | No | No |
| 16634994 | PROGRAMMABLE SOFT ROBOT | January 2020 | January 2022 | Allow | 23 | 0 | 0 | No | No |
| 16627583 | METHODS OF SYNTHESIZING NICOTINAMIDE RIBOSIDE | December 2019 | October 2022 | Allow | 33 | 1 | 1 | Yes | No |
| 16626221 | NUCLEIC ACID EXTRACTION MATERIALS, SYSTEMS, AND METHODS | December 2019 | March 2022 | Allow | 27 | 3 | 0 | Yes | No |
| 16717811 | SYNTHETIC ROUTE TO 2'-DEOXY-2',2'-DIFLUOROTETRAHYDROURIDINES | December 2019 | February 2021 | Allow | 14 | 1 | 0 | No | No |
| 16713711 | NICOTINAMIDE MONONUCLEOTIDE DERIVATIVES AND THEIR USES | December 2019 | May 2022 | Allow | 29 | 1 | 0 | No | No |
| 16712124 | BETALAIN COMPOSITIONS AND METHODS THEREFOR | December 2019 | February 2021 | Allow | 14 | 1 | 0 | No | No |
| 16622223 | METHODS FOR MODIFYING RNA SPLICING | December 2019 | October 2022 | Allow | 34 | 1 | 0 | Yes | No |
| 16710724 | INCLUSION COMPLEXES OF AN HCV NS5B INHIBITOR AND USES THEREOF | December 2019 | November 2021 | Allow | 24 | 0 | 0 | No | No |
| 16709060 | CRYSTALLINE FORMS OF NICOTINOYL RIBOSIDES AND DERIVATIVES THEREOF, AND METHODS OF PREPARATION THEREOF | December 2019 | October 2021 | Allow | 22 | 0 | 0 | No | No |
| 16619504 | TUNICAMYCIN ANALOGUES | December 2019 | November 2020 | Allow | 12 | 0 | 0 | No | No |
| 16698422 | METHODS FOR DECREASING THE INCIDENCE OF NECROTIZING ENTEROCOLITIS IN INFANTS, TODDLERS, OR CHILDREN USING HUMAN MILK OLIGOSACCHARIDES | November 2019 | February 2023 | Allow | 38 | 4 | 0 | No | No |
| 16615585 | ANTIBACTERIAL AGENTS INCLUDING HISTIDINE KINASE INHIBITORS | November 2019 | May 2022 | Allow | 30 | 1 | 0 | Yes | No |
| 16612414 | PHOTOSENSITIZERS AND METHOD OF TREATING CANCER USING THE SAME | November 2019 | September 2022 | Abandon | 34 | 1 | 0 | No | No |
| 16680054 | METHODS FOR DECREASING THE INCIDENCE OF NECROTIZING ENTEROCOLITIS IN INFANTS, TODDLERS, OR CHILDREN USING HUMAN MILK OLIGOSACCHARIDES | November 2019 | July 2021 | Allow | 20 | 2 | 0 | No | No |
| 16675785 | DRUG FORMULATIONS | November 2019 | March 2021 | Allow | 16 | 1 | 0 | Yes | No |
| 16609800 | METHOD OF PREVENTING OF SYSTEMIC-TO-PULMONARY-ARTERY SHUNT THROMBOSIS | October 2019 | November 2020 | Allow | 13 | 1 | 0 | No | No |
| 16609126 | BIS 2'-5'-RR-(3'F-A)(3'F-A) CYCLIC DINUCLEOTIDE COMPOUND AND USES THEREOF | October 2019 | December 2020 | Allow | 13 | 0 | 0 | No | No |
| 16659093 | COMPOSITIONS AND METHODS FOR ACTIVATING "STIMULATOR OF INTERFERON GENE" - DEPENDENT SIGNALLING | October 2019 | February 2021 | Allow | 16 | 1 | 0 | No | No |
| 16600336 | TRINUCLEOTIDE MRNA CAP ANALOGS | October 2019 | November 2020 | Allow | 13 | 0 | 0 | No | No |
| 16585705 | METHODS FOR TREATING CANCER USING PURINE ANALOGS BY DEPLETING INTRACELLULAR ATP | September 2019 | March 2021 | Allow | 18 | 1 | 0 | No | No |
| 16573325 | METHOD FOR TREATING CANCER WITH COMBINATION THERAPY | September 2019 | October 2020 | Allow | 13 | 1 | 0 | No | No |
| 16556690 | PHARMACEUTICAL COMPOUNDS AND USES THEREOF | August 2019 | April 2022 | Allow | 32 | 3 | 0 | Yes | No |
| 16557768 | PRODRUG COMPOUNDS AND THEIR USES | August 2019 | August 2020 | Allow | 11 | 1 | 0 | No | No |
| 16487813 | NOVEL IMMUNE STIMULATING COMPOUND | August 2019 | March 2021 | Allow | 19 | 1 | 0 | Yes | No |
| 16487789 | NOVEL IMMUNE STIMULATING MACROLIDES | August 2019 | March 2021 | Allow | 19 | 1 | 0 | Yes | No |
| 16487811 | NOVEL IMMUNE STIMULATING MACROLIDES | August 2019 | March 2021 | Allow | 19 | 1 | 0 | No | No |
| 16487695 | FLAVANONES FOR USE IN TREATING VISCERAL HYPERSENSITIVITY | August 2019 | June 2021 | Allow | 22 | 2 | 0 | No | No |
| 16486694 | PHENAZINE DERIVATIVES AS ANTIMICROBIAL AGENTS | August 2019 | March 2021 | Allow | 19 | 1 | 0 | No | No |
| 16541490 | COMBINATIONS AND METHODS COMPRISING A CAPSID ASSEMBLY INHIBITOR | August 2019 | September 2020 | Allow | 14 | 1 | 0 | No | No |
| 16533194 | PYRROLOPYRIMIDINE NUCLEOSIDES AND ANALOGS THEREOF | August 2019 | October 2020 | Allow | 15 | 1 | 0 | No | No |
| 16520372 | METHOD OF USING PROTEIN KINASE A ACTIVATOR AND INHIBITOR USED IN PREPARATION OF DRUGS FOR TREATING DISEASES ASSOCIATED WITH CHANGES IN PLATELET COUNTS AND FOR INHIBITING AND PROMOTING PLATELET APOPTOSIS | July 2019 | October 2022 | Abandon | 39 | 3 | 0 | Yes | No |
| 16478864 | CYCLIC DINUCLEOTIDES AS STING AGONISTS | July 2019 | January 2021 | Allow | 18 | 1 | 0 | No | No |
| 16478721 | IDOXURIDINE AND ITS ANALOGS AS NEUROPROTECTANS FOR THE TREATMENT OF PARKINSONISM | July 2019 | April 2021 | Allow | 21 | 2 | 0 | No | No |
| 16478121 | Combination Therapy For Treating Cancer | July 2019 | May 2022 | Allow | 34 | 3 | 0 | No | No |
| 16475832 | MODULATING NUDIX HOMOLOGY DOMAIN (NHD) WITH NICOTINAMIDE MONONUCLEOTIDE ANALOGS AND DERIVATIVES OF SAME | July 2019 | September 2022 | Abandon | 39 | 2 | 0 | No | Yes |
| 16454457 | Crystal Forms of �-Nicotinamide Mononucleotidt | June 2019 | March 2021 | Allow | 20 | 1 | 0 | No | No |
| 16455490 | AMINO ACID COMPOUNDS WITH UNBRANCHED LINKERS AND METHODS OF USE | June 2019 | November 2021 | Allow | 29 | 2 | 1 | Yes | No |
| 16442061 | COMPOSITION AND USES THEREOF | June 2019 | September 2021 | Allow | 27 | 2 | 0 | No | No |
| 16415325 | TREATMENT OF LEUKEMIA VIA THE ADMINISTRATION OF DOT1L INHIBITOR PINOMETOSTAT | May 2019 | March 2021 | Abandon | 22 | 1 | 0 | No | No |
| 16414593 | FUNCTIONALIZATION AND PURIFICATION OF MOLECULES BY REVERSIBLE GROUP EXCHANGE | May 2019 | February 2021 | Allow | 21 | 1 | 0 | No | No |
| 16402891 | DOT1L INHIBITION IN PATIENTS WITH MN1-HIGH AML | May 2019 | January 2021 | Abandon | 21 | 1 | 0 | No | No |
| 16345625 | COMPOSITIONS COMPRISING DESAMINOTYROSINE AND USES THEREOF TO ENHANCE TYPE I INTERFERON STIMULATION | April 2019 | March 2021 | Allow | 22 | 1 | 0 | No | No |
| 16344317 | NUCLEOSIDE PHOSPHATE COMPOUND AND PREPARATION METHOD AND USE THEREOF | April 2019 | September 2020 | Allow | 16 | 0 | 0 | Yes | No |
| 16391067 | CANCER CHEMOTHERAPY EMPLOYING HALOGENATED ANALOGS OF THYMIDINE | April 2019 | March 2021 | Allow | 22 | 2 | 0 | No | No |
| 16386886 | NOVEL TLR4 INHIBITORS FOR THE TREATMENT OF HUMAN INFECTIOUS AND INFLAMMATORY DISORDERS | April 2019 | October 2020 | Allow | 18 | 1 | 0 | No | No |
| 16384080 | Compositions and Methods for Reverse Automated Nucleic Acid Synthesis | April 2019 | November 2020 | Allow | 19 | 1 | 0 | No | No |
| 16374795 | Compositions and Methods for Synthesis of Phosphorylated Molecules | April 2019 | January 2021 | Allow | 22 | 1 | 0 | No | No |
| 16375445 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF LYSOSOMAL STORAGE DISORDERS AND DISORDERS CHARACTERIZED BY LYSOSOMAL DYSFUNCTION | April 2019 | March 2021 | Allow | 23 | 2 | 0 | No | No |
| 16375521 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF LYSOSOMAL STORAGE DISORDERS AND DISORDERS CHARACTERIZED BY LYSOSOMAL DYSFUNCTION | April 2019 | October 2020 | Abandon | 19 | 1 | 0 | No | No |
| 16374461 | INORGANIC SALTS OF NICOTINIC ACID MONONUCLEOTIDE AS ANTI-AGING AGENTS | April 2019 | January 2020 | Allow | 9 | 2 | 0 | Yes | No |
| 16338975 | INHIBITORS OF ADENOSINE 5'-NUCLEOTIDASE | April 2019 | March 2021 | Allow | 23 | 2 | 0 | Yes | No |
| 16364760 | METHODS FOR THE USE OF 5'-ADENOSINE DIPHOSPHATE RIBOSE (ADPR) | March 2019 | December 2020 | Allow | 21 | 2 | 0 | No | No |
| 16362130 | COMPOSITIONS AND METHODS FOR MODULATION OF NICOTINAMIDE ADENINE DINUCLEOTIDE | March 2019 | February 2020 | Allow | 11 | 2 | 0 | Yes | No |
| 16361810 | COMPOSITIONS AND METHODS FOR TREATING RETINAL DEGRADATION | March 2019 | September 2020 | Allow | 18 | 1 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner LEWIS, PATRICK T.
With a 0.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 21.4% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner LEWIS, PATRICK T works in Art Unit 1623 and has examined 632 patent applications in our dataset. With an allowance rate of 63.8%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 28 months.
Examiner LEWIS, PATRICK T's allowance rate of 63.8% places them in the 26% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.
On average, applications examined by LEWIS, PATRICK T receive 1.55 office actions before reaching final disposition. This places the examiner in the 26% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by LEWIS, PATRICK T is 28 months. This places the examiner in the 66% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.
Conducting an examiner interview provides a +3.0% benefit to allowance rate for applications examined by LEWIS, PATRICK T. This interview benefit is in the 25% percentile among all examiners. Recommendation: Interviews provide a below-average benefit with this examiner.
When applicants file an RCE with this examiner, 30.5% of applications are subsequently allowed. This success rate is in the 63% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.
This examiner enters after-final amendments leading to allowance in 56.8% of cases where such amendments are filed. This entry rate is in the 84% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
This examiner withdraws rejections or reopens prosecution in 86.7% of appeals filed. This is in the 80% percentile among all examiners. Of these withdrawals, 92.3% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 59.6% are granted (fully or in part). This grant rate is in the 61% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 4.1% of allowed cases (in the 84% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.